Creatine During Menopause: What the CONCRET-MENOPA Trial Found

The 2025 CONCRET-MENOPA randomized controlled trial studied 36 perimenopausal and menopausal women over 8 weeks. Results showed improved cognitive function, increased brain creatine levels, and improved reaction time with creatine supplementation — with no severe adverse effects. This is significant because menopause is associated with brain fog, sleep disruption, muscle loss, and joint pain — all areas where creatine shows emerging benefit. The trial confirmed safety and tolerability in this population, and the cognitive improvements were particularly notable. Brain energy metabolism declines during menopause due to reduced estrogen, and the phosphocreatine system appears to partially compensate — making supplementation especially relevant for menopausal women seeking cognitive and physical support.